Compare AbbVie Inc (ABBV) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Meta Platforms Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Meta Platforms Inc trades at $603.5 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 3.5× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | META | |
|---|---|---|
Market Cap | $449.91B | $1.56T |
Sector | Health | Media |
52-Week High | $261.07 | $790.00 |
52-Week Low | $184.85 | $525.72 |
Enterprise Value | $513.38B | $1.57T |
Dividend Yield | 2.72% | 0.34% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
META trades at $603.03, up 0.46% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $7.31 exceeding the $6.70 estimate. Revenue grew to $201.0B in 2025, and profitability remains robust with a net margin of 32.84%. Recent news highlights the launch of the Muse Spark AI model, driving positive sentiment.
The outlook is positive given analyst consensus with a $826.50 price target and 79% buy ratings. Key opportunities include AI monetization and revenue growth, while risks involve regulatory lawsuits and high capital expenditure. The stock offers upside potential but faces execution and legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
